Monte Rosa Therapeutics Inc (GLUE)

  • Get an in-depth profile of Monte Rosa Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
2.96 -0.04 (-1.33%)
Closed USD Disclaimer
3.02 +0.06 (+2.03%)

Monte Rosa Therapeutics Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
118
Equity Type
ORD
Monte Rosa Therapeutics, Inc. is a biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The Company has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product development on therapeutic targets is backed by biological and genetic rationale discovering and developing novel medicines. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors.
Contact Information
Address
Boston,02210 United States
Phone
617 949 2643
Fax
-
Web
https://www.monterosatx.com
Top Executives
Name
Age
Since
Title
Markus Warmuth 50 2020 President, CEO & Director
Michael Rape 0 0000 Member of Scientific Advisory Board
Kimberly Lynn Blackwell 53 2020 Independent Director & Member of Scientific Advisory Board
Nir London 0 2021 Member of Scientific Advisory Board
Eliezer Van Allen 0 0000 Member of Scientific Advisory Board
Ali Behbahani 46 2020 Independent Director
Chandra Paul Leo 51 2020 Independent Director
Jan Skvarka 55 2023 Independent Director
Andrew Newman Schiff 58 2020 Independent Chairman of the Board
Nicolas Thoma 0 0000 Chairman of Scientific Advisory Board
Christine E. Siu 46 2020 Independent Director
David P. Schenkein 66 0000 Member of Scientific Advisory Board
Alexander Mayweg 48 2018 Non-Executive Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.